BackgroundMore than 50% of the patients with heart failure have normal ejection
fraction (HFNEF). Iodine-123 metaiodobenzylguanidine (123I-MIBG)
scintigraphy and cardiopulmonary exercise test (CPET) are prognostic markers
in HFNEF. Nebivolol is a beta-blocker with vasodilating properties.ObjectivesTo evaluate the impact of nebivolol therapy on CPET and123I-MIBG
scintigraphic parameters in patients with HFNEF.MethodsTwenty-five patients underwent 123I-MIBG scintigraphy to determine the
washout rate and early and late heart-to-mediastinum ratios. During the
CPET, we analyzed the systolic blood pressure (SBP) response, heart rate
(HR) during effort and recovery (HRR), and oxygen uptake (VO2).
After the initial evaluation, we divided our cohort into control and
intervention groups. We then started nebivolol and repeated the tests after
3 months.ResultsAfter treatment, the intervention group showed improvement in rest SBP (149
mmHg [143.5-171 mmHg] versus 135 mmHg [125-151 mmHg, p = 0.016]), rest HR
(78 bpm [65.5-84 bpm] versus 64.5 bpm [57.5-75.5 bpm, p = 0.028]), peak SBP
(235 mmHg [216.5-249 mmHg] versus 198 mmHg [191-220.5 mmHg], p = 0.001),
peak HR (124.5 bpm [115-142 bpm] versus 115 bpm [103.7-124 bpm], p= 0.043),
HRR on the 1st minute (6.5 bpm [4.75-12.75 bpm] versus 14.5 bpm [6.7-22
bpm], p = 0.025) and HRR on the 2nd minute (15.5 bpm [13-21.75 bpm] versus
23.5 bpm [16-31.7 bpm], p = 0.005), but no change in peak VO2 and
123I-MIBG scintigraphic parameters.ConclusionDespite a better control in SBP, HR during rest and exercise, and improvement
in HRR, nebivolol failed to show a positive effect on peak VO2 and 123I-MIBG
scintigraphic parameters. The lack of effect on adrenergic activity may be
the cause of the lack of effect on functional capacity.